Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand

McDonald, Christine F; Crockett, Alan; Young, Iven H.

doi:10.5694/j.1326-5377.2005.tb06848.x

Cited by 77 publications

(69 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over one‐quarter of patients (60 of 221 admissions) were discharged on domiciliary oxygen therapy. Despite clear guidelines indicating that eligibility for provision of this therapy requires documented hypoxaemia, 23 only 10 of these 60 admissions had documented PaO 2 of less than 60 mmHg while breathing room air. More than a quarter (28%) of those discharged on domiciliary oxygen had not undergone ABG analysis at all during admission.…”

Section: Discussionmentioning

confidence: 99%

Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines

Pretto

McDonald

Wark

et al. 2012

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines

Pretto

McDonald

Wark

et al. 2012

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…We excluded smokers from this study because in our centre and elsewhere smokers would not be eligible for potential therapeutic intervention with domiciliary oxygen 25. We were therefore able to estimate that the overall prevalence of nocturnal desaturation in non-smoking COPD patients not on long term oxygen therapy was less than 5%.…”

Section: Discussionmentioning

confidence: 99%

Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep

Lewis

Fergusson

Eaton

et al. 2009

Thorax

134

View full text Add to dashboard Cite

Background and aims:The clinical impact of nocturnal desaturation on health related quality of life (HRQL) and sleep in chronic obstructive pulmonary disease (COPD) has been little studied. The aim of this study was to evaluate the prevalence and clinical impact of nocturnal desaturation in a typical outpatient population with COPD. Patients and methods: Between 2002 and 2005, consecutive patients with COPD attending outpatient services at the study centre underwent resting oximetry if they were not on domiciliary oxygen therapy. If their resting saturations were less than 95%, overnight pulse oximetry was performed. Significant nocturnal desaturation was defined as spending more than 30% of at least one of two nights with a saturation of less than 90%. The Chronic Respiratory Questionnaire (CRQ) and Short Form 36 (SF36) were used to assess HRQL, and the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Score (ESS) and Functional Outcomes of Sleep (FOSQ) questionnaires were used to assess sleep quality and daytime function. Results: Of 1104 patients, 803 underwent resting oximetry and 79 had resting oxygen saturations of less than 95%. Of these, 59 agreed to undergo overnight oximetry (mean age 70 years, forced expiratory volume in 1 s 37.2% predicted, resting PO 2 on air 8.9 kPa). Significant nocturnal desaturation was seen in 29 (49.2%) of the 59 subjects. Assuming the less hypoxic patients do not have nocturnal desaturation, the prevalence of nocturnal desaturation in the whole clinic population could be estimated at 4.8%. There were no significant differences in CRQ, SF36, PSQI, ESS or FOSQ scores for desaturators compared with non-desaturators. Conclusion: Significant nocturnal desaturation was common in patients with COPD with resting saturations of less than 95%, but was estimated to have a prevalence of less than 5% in the whole outpatient population. Nocturnal desaturation was not associated with impairment of HRQL, sleep quality or daytime function.Nocturnal desaturation may occur in chronic obstructive pulmonary disease (COPD) in the absence of severe daytime hypoxaemia. The prevalence of such ''isolated'' nocturnal desaturation has previously been reported at between 25% and 70%.1-3 However, these studies have varied in their inclusion criteria and the definition of nocturnal desaturation used, and therefore uncertainty remains as to the true prevalence of isolated nocturnal desaturation in the stable COPD outpatient population.Previously, attention focused on the potential adverse effects of nocturnal desaturation on pulmonary haemodynamics in COPD, but a recent study found no difference in pulmonary artery pressures over 2 years in patients with and without nocturnal desaturation. 4 However, the clinical impact of nocturnal desaturation remains unclear. Four studies have examined the effects of nocturnal desaturation and its correction with oxygen therapy on sleep architecture and quality.5-8 These studies were small, short term and sleep laboratory based, employed variable methodo...

show abstract

“…In a randomized controlled crossover study of 16 patients with COPD-related PH, Iloprost failed to improve 6MWT as compared to placebo and was associated with impaired oxygenation at rest [91]. However, in a further study involving 10 COPD patients with PH, low dose inhaled Iloprost was seen to improve gas exchange and exercise tolerance 30 minutes after administration [92]. …”

Section: Treatmentmentioning

confidence: 99%

Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease

Zangiabadi

Pasquale

Sajkov

2014

BioMed Research International

View full text Add to dashboard Cite

Group 3 pulmonary hypertension (PH) is a common complication of chronic lung disease (CLD), including chronic obstructive pulmonary disease (COPD), interstitial lung disease, and sleep-disordered breathing. Development of PH is associated with poor prognosis and may progress to right heart failure, however, in the majority of the patients with CLD, PH is mild to moderate and only a small number of patients develop severe PH. The pathophysiology of PH in CLD is multifactorial and includes hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, small vessel destruction, and fibrosis. The effects of PH on the right ventricle (RV) range between early RV remodeling, hypertrophy, dilatation, and eventual failure with associated increased mortality. The golden standard for diagnosis of PH is right heart catheterization, however, evidence of PH can be appreciated on clinical examination, serology, radiological imaging, and Doppler echocardiography. Treatment of PH in CLD focuses on management of the underlying lung disorder and hypoxia. There is, however, limited evidence to suggest that PH-specific vasodilators such as phosphodiesterase-type 5 inhibitors, endothelin receptor antagonists, and prostanoids may have a role in the treatment of patients with CLD and moderate-to-severe PH.

show abstract

Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand

Cited by 77 publications

References 22 publications

Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines

Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines

Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep

Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease

Contact Info

Product

Resources

About